Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9454
Title: Prostate cancer: are new prognostic markers on the horizon?
Authors: Lijovic, M;Fabiani, Mark E;Bader, J;Frauman, Albert G
Affiliation: Molecular Immunology Laboratory, Clinical Pharmacology and Therapeutics Unit, Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084, Australia.
Issue Date: 1-Aug-2000
Citation: Prostate Cancer and Prostatic Diseases; 3(2): 62-65
Abstract: Current diagnostic methods in prostate cancer are lacking in their ability to predict individual patient outcome which highlights the need for more sensitive prognostic markers. Biological markers are seen as attractive and relevant candidates in current efforts to improve prognostic methods. Since metastasis is the most important component of cancer progression and mortality, markers which are able to predict the likely acquisition of the metastatic phenotype, before the onset of metastases, would be extremely useful clinically. This review outlines various metastasis suppressor genes and metastasis promoters which might have potential prognostic use in prostate cancer. Prostate Cancer and Prostatic Diseases (2000) 3, 62-65
Internal ID Number: 12497101
URI: http://ahro.austin.org.au/austinjspui/handle/1/9454
DOI: 10.1038/sj.pcan.4500408
URL: http://www.ncbi.nlm.nih.gov/pubmed/12497101
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.